In our current study, we demonstrated an unequal contribution of the two important Ras downstream pathways, PI-3K and MEK/MAPK, in mediating increased drug resistance in MCF7 human breast cancer cells following the expression of a constitutively active Ras (H-RasG12V). Here, MAP2K7 is linked to breast cancer.